Skip to main content
Journal cover image

High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis

Publication ,  Conference
Reau, N; Muir, AJ; Pockros, P; Reddy, RK; Pedrosa, M; Larsen, L; Enejosa, J; Howell, C
Published in: American Journal of Gastroenterology
October 2015

Duke Scholars

Published In

American Journal of Gastroenterology

DOI

ISSN

0002-9270

Publication Date

October 2015

Volume

110

Start / End Page

S859 / S859

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reau, N., Muir, A. J., Pockros, P., Reddy, R. K., Pedrosa, M., Larsen, L., … Howell, C. (2015). High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis. In American Journal of Gastroenterology (Vol. 110, pp. S859–S859). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.14309/00000434-201510001-02038
Reau, Nancy, Andrew J. Muir, Paul Pockros, Rajender K. Reddy, Marcos Pedrosa, Lois Larsen, Jeffrey Enejosa, and Charles Howell. “High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis.” In American Journal of Gastroenterology, 110:S859–S859. Ovid Technologies (Wolters Kluwer Health), 2015. https://doi.org/10.14309/00000434-201510001-02038.
Reau N, Muir AJ, Pockros P, Reddy RK, Pedrosa M, Larsen L, et al. High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis. In: American Journal of Gastroenterology. Ovid Technologies (Wolters Kluwer Health); 2015. p. S859–S859.
Reau, Nancy, et al. “High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis.” American Journal of Gastroenterology, vol. 110, Ovid Technologies (Wolters Kluwer Health), 2015, pp. S859–S859. Crossref, doi:10.14309/00000434-201510001-02038.
Reau N, Muir AJ, Pockros P, Reddy RK, Pedrosa M, Larsen L, Enejosa J, Howell C. High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis. American Journal of Gastroenterology. Ovid Technologies (Wolters Kluwer Health); 2015. p. S859–S859.
Journal cover image

Published In

American Journal of Gastroenterology

DOI

ISSN

0002-9270

Publication Date

October 2015

Volume

110

Start / End Page

S859 / S859

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences